Literature DB >> 28958624

Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.

Arun K Ghosh1, W Sean Fyvie2, Margherita Brindisi2, Melinda Steffey2, Johnson Agniswamy3, Yuan-Fang Wang3, Manabu Aoki4, Masayuki Amano4, Irene T Weber3, Hiroaki Mitsuya5.   

Abstract

Design, synthesis, and evaluation of a new class of HIV-1 protease inhibitors containing diverse flexible macrocyclic P1'-P2' tethers are reported. Inhibitor 5a with a pyrrolidinone-derived macrocycle exhibited favorable enzyme inhibitory and antiviral activity (Ki=13.2nM, IC50=22nM). Further incorporation of heteroatoms in the macrocyclic skeleton provided macrocyclic inhibitors 5m and 5o. These compounds showed excellent HIV-1 protease inhibitory (Ki=62pM and 14pM, respectively) and antiviral activity (IC50=5.3nM and 2.0nM, respectively). Inhibitor 5o also remained highly potent against a DRV-resistant HIV-1 variant.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug resistance; HIV protease; Macrocyclic inhibitors; P1′-P2′ ligands; Structure-based design

Mesh:

Substances:

Year:  2017        PMID: 28958624      PMCID: PMC5647257          DOI: 10.1016/j.bmcl.2017.09.003

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  29 in total

Review 1.  Current status and prospects of HIV treatment.

Authors:  Tomas Cihlar; Marshall Fordyce
Journal:  Curr Opin Virol       Date:  2016-03-28       Impact factor: 7.090

2.  In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.

Authors:  Yasuhiro Koh; Masayuki Amano; Tomomi Towata; Matthew Danish; Sofiya Leshchenko-Yashchuk; Debananda Das; Maki Nakayama; Yasushi Tojo; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

3.  Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.

Authors:  Arun K Ghosh; Lisa M Swanson; Hanna Cho; Sofiya Leshchenko; Khaja Azhar Hussain; Stephanie Kay; D Eric Walters; Yasuhiro Koh; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

4.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.

Authors:  J Erickson; D J Neidhart; J VanDrie; D J Kempf; X C Wang; D W Norbeck; J J Plattner; J W Rittenhouse; M Turon; N Wideburg
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

5.  TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

Authors:  Sandra De Meyer; Hilde Azijn; Dominique Surleraux; Dirk Jochmans; Abdellah Tahri; Rudi Pauwels; Piet Wigerinck; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

Authors:  Yasuhiro Koh; Debananda Das; Sofiya Leschenko; Hirotomo Nakata; Hiromi Ogata-Aoki; Masayuki Amano; Maki Nakayama; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

7.  Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.

Authors:  Ravindra Gupta; Andrew Hill; Anthony W Sawyer; Deenan Pillay
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

8.  Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Authors:  Yasuhiro Koh; Hirotomo Nakata; Kenji Maeda; Hiromi Ogata; Geoffrey Bilcer; Thippeswamy Devasamudram; John F Kincaid; Peter Boross; Yuan-Fang Wang; Yunfeng Tie; Patra Volarath; Laquasha Gaddis; Robert W Harrison; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.

Authors:  Arun K Ghosh; Gary E Schiltz; Linah N Rusere; Heather L Osswald; D Eric Walters; Masayuki Amano; Hiroaki Mitsuya
Journal:  Org Biomol Chem       Date:  2014-09-21       Impact factor: 3.876

10.  Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals.

Authors:  Stéphane Hué; Robert J Gifford; David Dunn; Esther Fernhill; Deenan Pillay
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.